Pancreatic Cancer Research

ResearcherTrinity College DublinActive in the last 2 years

Kevin C. Conlon

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-3703-7080; OpenAlex author ID A5066966766. Sources: OpenAlex.

Their work

Papers
23 (first author 1, last author 5)
Trials
0
Grants
0
Labs led
1
Collaborators
96
Papers, trials and grants by year

2012: 1 paper · 2013: 2 papers · 2014: 4 papers · 2015: none · 2016: none · 2017: none · 2018: 3 papers · 2019: 2 papers · 2020: 3 papers · 2021: none · 2022: 2 papers · 2023: 2 papers · 2024: 1 paper · 2025: 3 papers

Papers 23

  1. Adjuvant Chemotherapy After Resection of Localized Pancreatic Adenocarcinoma Following Preoperative FOLFIRINOX. Co-author DOI 10.1001/jamaoncol.2024.5917↗
  2. Multi-omic biomarker panel in pancreatic cyst fluid and serum predicts patients at a high risk of pancreatic cancer development. Co-author DOI 10.1038/s41598-024-83742-4↗
  3. Validation of the PANAMA Score for Survival and Benefit of Adjuvant Therapy in Patients With Resected Pancreatic Cancer after Neoadjuvant FOLFIRINOX. Co-author DOI 10.1097/sla.0000000000006650↗
  4. Updates on pancreatic cancer treatment - invited special issue. Co-author DOI 10.1097/js9.0000000000002086↗
  5. Surgical and Oncological Outcomes After Preoperative FOLFIRINOX Chemotherapy in Resected Pancreatic Cancer: An International Multicenter Cohort Study. Co-author DOI 10.1245/s10434-022-12387-2↗
  6. Alteration in Levels of Specific miRNAs and Their Potential Protein Targets between Human Pancreatic Cancer Samples, Adjacent Normal Tissue, and Xenografts Der… Co-author DOI 10.3390/life13030608↗
  7. Pre-operative radiomics model for prognostication in resectable pancreatic adenocarcinoma with external validation. Co-author DOI 10.1007/s00330-021-08314-w↗
  8. Measurement of Body Composition in Pancreatic Cancer: A Systematic Review, Meta-Analysis, and Recommendations for Future Study Design. Last author DOI 10.1159/000524575↗
  9. Evaluation of Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer After Neoadjuvant FOLFIRINOX Treatment. Co-author DOI 10.1001/jamaoncol.2020.3537↗
  10. Proteomic Analysis of Cell Lines and Primary Tumors in Pancreatic Cancer Identifies Proteins Expressed Only In Vitro and Only In Vivo. Co-author DOI 10.1097/mpa.0000000000001633↗
  11. Establishment and Characterisation by Expression Microarray of Patient-Derived Xenograft Panel of Human Pancreatic Adenocarcinoma Patients. Co-author DOI 10.3390/ijms21030962↗
  12. Characterising the impact of body composition change during neoadjuvant chemotherapy for pancreatic cancer. Last author DOI 10.1016/j.pan.2019.07.039↗
  13. The Role of Staging Laparoscopy in Resectable and Borderline Resectable Pancreatic Cancer: A Systematic Review and Meta-Analysis. Last author DOI 10.1159/000488372↗
  14. Sarcopenia-A New Frontier in the Management Care of Patients With Borderline Resectable Pancreatic Cancer. First author DOI 10.1001/jamasurg.2018.1006↗
  15. Preoperative CT in patients with surgically resectable pancreatic adenocarcinoma: does the time interval between CT and surgery affect survival? Co-author DOI 10.1007/s00261-017-1254-9↗
  16. A Comparative Quantitative LC-MS/MS Profiling Analysis of Human Pancreatic Adenocarcinoma, Adjacent-Normal Tissue, and Patient-Derived Tumour Xenografts. Co-author DOI 10.3390/proteomes6040045↗
  17. Pancreatic metastasectomy: experience of the Irish National Surgical Centre for Pancreatic Cancer. Last author DOI 10.1007/s11845-014-1175-3↗
  18. Borderline resectable pancreatic cancer: a consensus statement by the International Study Group of Pancreatic Surgery (ISGPS). Co-author DOI 10.1016/j.surg.2014.02.001↗
  19. Extended pancreatectomy in pancreatic ductal adenocarcinoma: definition and consensus of the International Study Group for Pancreatic Surgery (ISGPS). Co-author DOI 10.1016/j.surg.2014.02.009↗
  20. Definition of a standard lymphadenectomy in surgery for pancreatic ductal adenocarcinoma: a consensus statement by the International Study Group on Pancreatic … Co-author DOI 10.1016/j.surg.2014.06.016↗
  21. Identification of distinct phenotypes of locally advanced pancreatic adenocarcinoma. Co-author DOI 10.1007/s12029-012-9419-9↗
  22. Prognostic role of neutrophil-to-lymphocyte ratio in advanced pancreatic ductal adenocarcinoma: impact of baseline fluctuation and changes during chemotherapy. Co-author DOI 10.1177/030089161309900413↗
  23. Invasive markers identified by gene expression profiling in pancreatic cancer. Last author DOI 10.1016/j.pan.2011.12.011↗

Closest collaborators

The 25 strongest of 96 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Oonagh M. Griffin · 5 shared papers, 2018–2025 · strength 0.67
  2. Paula Meleady · 4 shared papers, 2018–2025 · strength 0.53
  3. Roberto Coppola · 1 shared paper, 2024 · strength 0.46
  4. Martin M. Clynes · 5 shared papers, 2012–2023 · strength 0.43
  5. Ray McDermott · 5 shared papers, 2013–2023 · strength 0.43
  6. Sandra Roche · 4 shared papers, 2018–2023 · strength 0.40
  7. Fiona O’Neill · 4 shared papers, 2018–2023 · strength 0.40
  8. Paul F. Ridgway · 4 shared papers, 2012–2025 · strength 0.33
  9. Robert M. Straubinger · 3 shared papers, 2018–2023 · strength 0.30
  10. Morgan Bonds · 2 shared papers, 2020–2025 · strength 0.22
  11. Giuseppe Malleo · 2 shared papers, 2020–2025 · strength 0.22
  12. Alberto Balduzzi · 2 shared papers, 2020–2025 · strength 0.22
  13. Tobias Keck · 2 shared papers, 2020–2025 · strength 0.22
  14. Asif Halimi · 2 shared papers, 2020–2025 · strength 0.22
  15. Adnan A. Alseidi · 2 shared papers, 2020–2025 · strength 0.22
  16. Daniel Pietrasz · 2 shared papers, 2020–2025 · strength 0.22
  17. Johan Gagnière · 2 shared papers, 2020–2025 · strength 0.22
  18. Stijn R. van Roessel · 2 shared papers, 2020–2025 · strength 0.22
  19. Frederik Christiaan Berrevoet · 2 shared papers, 2020–2025 · strength 0.22
  20. Eran van Veldhuisen · 2 shared papers, 2020–2025 · strength 0.22
  21. Thilo Hackert · 2 shared papers, 2020–2025 · strength 0.22
  22. Isabella M. Frigerio · 2 shared papers, 2020–2025 · strength 0.22
  23. Giovanni Butturini · 2 shared papers, 2020–2025 · strength 0.22
  24. Quisette P. Janssen · 2 shared papers, 2020–2025 · strength 0.22
  25. Hanneke W.M. van Laarhoven · 2 shared papers, 2020–2025 · strength 0.22

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.